MPN10 Tracker
Help patients monitor symptoms with the MPN10 tracker.
This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.
Image
Image
Resources to support you and your patients
JAKAVI® (ruxolitinib) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. JAKAVI® is also indicated for adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.1
This website is intended for healthcare professionals. Please do not direct patients to this page. Patient resources should be downloaded and forwarded to your patients. Alternatively, you can request hard copies from your local representative.
These resources have been developed by Novartis and are intended for healthcare professionals, to help you get the most out of treating with JAKAVI®.
Image
JAKAVI dosing timeline
JAKAVI dosing timeline
PDF
A JAKAVI® treatment timeline that can be used during your patient consultations.
Image
MF risk stratification
MF risk stratification
PDF
A guide to support MF patient risk stratification using the IPSS, DIPSS and DIPSS Plus scoring systems.
Image
A guide to JAKAVI in PV
A guide to JAKAVI in PV
PDF
A guide to the treatment with JAKAVI® for your patients with PV.
Image
MF and PV educational modules
MF and PV educational modules
Web Link
CPD-accredited modules on the treatment landscape, disease burden and management of MF and PV.
These resources have been developed by Novartis and are intended for patients who have been diagnosed with an MPN. These resources will help give patients the confidence and knowledge to discuss their disease and track symptoms effectively. Information provided in these resources should not be considered an alternative to advice from a healthcare professional. Please do not direct patients to this page. Patient resources should be downloaded and forwarded to your patients. Alternatively, you can request hard copies from your local representative.
Image
Patient symptom guide
Patient symptom guide
PDF
A guide to help patients identify and better understand symptoms related to their disease.
Image
MF essentials guide
MF essentials guide
PDF
A guide to support patients with MF who have been initiated on JAKAVI®.
Image
PV essentials guide
PV essentials guide
PDF
A guide to support patients with PV who have been initiated on JAKAVI®.
Video
4 mins 49 secs
Patient perspectives: “How MPN 10 helps me understand ‘my’ symptoms”
Video
- 23 Oct 2025
4 mins 49 secs
Watch two patients discuss their symptoms with a consultant nurse specialist and the advantages of using the validated tool, MPN 10, to monitor them.
DIPSS, dynamic international prognostic scoring system; HCP, healthcare professional; IPSS, international prognostic scoring system; MF, myelofibrosis; MPN, myeloproliferative neoplasm; PV, polycythaemia vera.
Reference
JAKAVI® (ruxolitinib) Summary of Product Characteristics.
UK | November 2025 | FA-11317792
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
